Trial Profile
A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-1
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Iclaprim (Primary) ; Vancomycin
- Indications Bacterial infections; Skin and soft tissue infections
- Focus Registrational; Therapeutic Use
- Acronyms REVIVE-1
- Sponsors Motif Bio
- 01 Aug 2019 According to a Motif Bio media release, the company has submitted a proposal (for a future study) for review in July 2019.The company has been granted a meeting, scheduled for 19th Sep 2019, with the Agency to discuss the proposed patient population and study design.
- 24 Jun 2019 Results of population pharmacokinetic (PK) Analysis of the Fixed Dose of Iclaprim in the REVIVE-1 and 2 studies presented at the ASM Microbe 2019
- 23 Jun 2019 According to a Motif Bio media release, results were presented at the American Society For Microbiology (ASM) Microbe 2019 meeting.